Natriumklorid Meda

The solution should not be administered orally or parenterally.

Do not use unless the product is clear and the pack intact. Discard any surplus after use. Natriumklorid Meda should be used with a nebuliser, only under the direction of a physician. Patients using nebuliser solutions at home should be warned that if the usual relief is diminished or the usual duration of action reduced, they should consult their doctor.

Not known.

Natriumklorid Meda is not expected to cause any undesirable effects in normal use.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard

Substantial oral ingestion may require the use of a diuretic to remove excess sodium.

Isotonic (0.9% w/v) sodium chloride solution is widely used for dilution purposes.

Adverse reactions possible when combined with:

• Benzodiazepines

• CNS depressants

• Antidepressants

• MAO inhibitors

• R52.1 – Chronic intractable pain
• R52.2 – Other chronic pain
• R52.9 – Unspecified pain

There are no findings of relevance to the prescriber other than those already mentioned elsewhere in the SPC. Please refer to the product to be reconstituted.

Adverse reactions possible when combined with:

• Benzodiazepines

• CNS depressants

• Antidepressants

• MAO inhibitors

Dispose of the medication in accordance with local regulations for medical waste.